Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life

Stina Syrjänen; Tim Waterboer; Marjut Rintala; Michael Pawlita; Kari Syrjänen; Karolina Louvanto; Seija Grenman

doi:10.1038/s41598-022-06343-z

Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life

Stina Syrjänen^*
, Tim Waterboer
, Marjut Rintala
, Michael Pawlita
, Kari Syrjänen
, Karolina Louvanto
, Seija Grenman

^*Tämän työn vastaava kirjoittaja

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

14 Sitaatiot (Scopus)

18 Lataukset (Pure)

Abstrakti

To assess the dynamics of human papillomavirus (HPV) serology, we analyzed HPV6-,11-,16-,18-, and 45 antibodies in infants during the first 36 months of their life. Serial serum samples of 276/327 mother–child pairs were collected at baseline (mothers) and at months 1, 2, 6, 12, 24 and 36 (offspring), and tested for HPVL1-antibodies using the GST-L1 assay. Concordance between maternal and infant HPV-antibody levels remained high until month-6 (p < = 0.001), indicating maternal antibody transfer. At 1 month, 40–62% of the infants tested seropositive to any of the 5 HPV-types. Between 1–3 years of age, 53% (58/109) of the children born to HPV-seronegative mothers tested HPV-seropositive. Times to positive seroconversion varied between13.4 and 18.7 months, and times to negative seroconversion (decay) between 8.5 and 9.9 months. Significant independent predictors of infants’ seroconversion to LR-HPV were hand warts and mother’s history of oral warts and seroconversion to LR-HPV. No predictors of seroconversion to HR-HPV were identified. Maternal HPV-IgG-antibodies are transferred to her offspring and remain detectable for 6 months, corroborating the IgG molecule’s half-life. Seroconversion to HPV-genotypes 6, 11, 16 and 18 was confirmed among children born to HPV-seronegative mothers, implicating an immune response to these HPV-genotypes during early infancy.

Alkuperäiskieli	Englanti
Artikkeli	2227
Julkaisu	Scientific Reports
Vuosikerta	12
DOI - pysyväislinkit	https://doi.org/10.1038/s41598-022-06343-z
Tila	Julkaistu - helmik. 2022
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Rahoitus

At different phases, the FFHPV study has received support from the Päivikki and Sakari Sohlberg Foundation, the Government Special Foundation for the Turku University Hospital, the Finnish Cancer Foundation, the Academy of Finland, the Finnish Cultural Foundation, the Turku University Foundation and the Cancer Foundations of South-Western Finland. HPV serology analyses were supported by a fellowship of the Peter and Traudl Engelhorn-Stiftung. The funders had no role in the design or conduct of the study.

Julkaisufoorumi-taso

Jufo-taso 1

!!ASJC Scopus subject areas

General

Pääsy asiakirjaan

10.1038/s41598-022-06343-zLisenssi: CC BY

s41598-022-06343-zFinal published version, 1,45 MBLisenssi: CC BY

https://urn.fi/URN:NBN:fi:tuni-202204294117Lisenssi: CC BY

Siteeraa tätä

@article{84b389ccc05d4a83adec4714ec36a67d,

title = "Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life",

abstract = "To assess the dynamics of human papillomavirus (HPV) serology, we analyzed HPV6-,11-,16-,18-, and 45 antibodies in infants during the first 36 months of their life. Serial serum samples of 276/327 mother–child pairs were collected at baseline (mothers) and at months 1, 2, 6, 12, 24 and 36 (offspring), and tested for HPVL1-antibodies using the GST-L1 assay. Concordance between maternal and infant HPV-antibody levels remained high until month-6 (p < = 0.001), indicating maternal antibody transfer. At 1 month, 40–62\% of the infants tested seropositive to any of the 5 HPV-types. Between 1–3 years of age, 53\% (58/109) of the children born to HPV-seronegative mothers tested HPV-seropositive. Times to positive seroconversion varied between13.4 and 18.7 months, and times to negative seroconversion (decay) between 8.5 and 9.9 months. Significant independent predictors of infants{\textquoteright} seroconversion to LR-HPV were hand warts and mother{\textquoteright}s history of oral warts and seroconversion to LR-HPV. No predictors of seroconversion to HR-HPV were identified. Maternal HPV-IgG-antibodies are transferred to her offspring and remain detectable for 6 months, corroborating the IgG molecule{\textquoteright}s half-life. Seroconversion to HPV-genotypes 6, 11, 16 and 18 was confirmed among children born to HPV-seronegative mothers, implicating an immune response to these HPV-genotypes during early infancy.",

author = "Stina Syrj{\"a}nen and Tim Waterboer and Marjut Rintala and Michael Pawlita and Kari Syrj{\"a}nen and Karolina Louvanto and Seija Grenman",

note = "Funding Information: At different phases, the FFHPV study has received support from the P{\"a}ivikki and Sakari Sohlberg Foundation, the Government Special Foundation for the Turku University Hospital, the Finnish Cancer Foundation, the Academy of Finland, the Finnish Cultural Foundation, the Turku University Foundation and the Cancer Foundations of South-Western Finland. HPV serology analyses were supported by a fellowship of the Peter and Traudl Engelhorn-Stiftung. The funders had no role in the design or conduct of the study. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = feb,

doi = "10.1038/s41598-022-06343-z",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

}

TY - JOUR

T1 - Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life

AU - Syrjänen, Stina

AU - Waterboer, Tim

AU - Rintala, Marjut

AU - Pawlita, Michael

AU - Syrjänen, Kari

AU - Louvanto, Karolina

AU - Grenman, Seija

N1 - Funding Information: At different phases, the FFHPV study has received support from the Päivikki and Sakari Sohlberg Foundation, the Government Special Foundation for the Turku University Hospital, the Finnish Cancer Foundation, the Academy of Finland, the Finnish Cultural Foundation, the Turku University Foundation and the Cancer Foundations of South-Western Finland. HPV serology analyses were supported by a fellowship of the Peter and Traudl Engelhorn-Stiftung. The funders had no role in the design or conduct of the study. Publisher Copyright: © 2022, The Author(s).

PY - 2022/2

Y1 - 2022/2

N2 - To assess the dynamics of human papillomavirus (HPV) serology, we analyzed HPV6-,11-,16-,18-, and 45 antibodies in infants during the first 36 months of their life. Serial serum samples of 276/327 mother–child pairs were collected at baseline (mothers) and at months 1, 2, 6, 12, 24 and 36 (offspring), and tested for HPVL1-antibodies using the GST-L1 assay. Concordance between maternal and infant HPV-antibody levels remained high until month-6 (p < = 0.001), indicating maternal antibody transfer. At 1 month, 40–62% of the infants tested seropositive to any of the 5 HPV-types. Between 1–3 years of age, 53% (58/109) of the children born to HPV-seronegative mothers tested HPV-seropositive. Times to positive seroconversion varied between13.4 and 18.7 months, and times to negative seroconversion (decay) between 8.5 and 9.9 months. Significant independent predictors of infants’ seroconversion to LR-HPV were hand warts and mother’s history of oral warts and seroconversion to LR-HPV. No predictors of seroconversion to HR-HPV were identified. Maternal HPV-IgG-antibodies are transferred to her offspring and remain detectable for 6 months, corroborating the IgG molecule’s half-life. Seroconversion to HPV-genotypes 6, 11, 16 and 18 was confirmed among children born to HPV-seronegative mothers, implicating an immune response to these HPV-genotypes during early infancy.

AB - To assess the dynamics of human papillomavirus (HPV) serology, we analyzed HPV6-,11-,16-,18-, and 45 antibodies in infants during the first 36 months of their life. Serial serum samples of 276/327 mother–child pairs were collected at baseline (mothers) and at months 1, 2, 6, 12, 24 and 36 (offspring), and tested for HPVL1-antibodies using the GST-L1 assay. Concordance between maternal and infant HPV-antibody levels remained high until month-6 (p < = 0.001), indicating maternal antibody transfer. At 1 month, 40–62% of the infants tested seropositive to any of the 5 HPV-types. Between 1–3 years of age, 53% (58/109) of the children born to HPV-seronegative mothers tested HPV-seropositive. Times to positive seroconversion varied between13.4 and 18.7 months, and times to negative seroconversion (decay) between 8.5 and 9.9 months. Significant independent predictors of infants’ seroconversion to LR-HPV were hand warts and mother’s history of oral warts and seroconversion to LR-HPV. No predictors of seroconversion to HR-HPV were identified. Maternal HPV-IgG-antibodies are transferred to her offspring and remain detectable for 6 months, corroborating the IgG molecule’s half-life. Seroconversion to HPV-genotypes 6, 11, 16 and 18 was confirmed among children born to HPV-seronegative mothers, implicating an immune response to these HPV-genotypes during early infancy.

U2 - 10.1038/s41598-022-06343-z

DO - 10.1038/s41598-022-06343-z

M3 - Article

C2 - 35140326

AN - SCOPUS:85124254147

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

M1 - 2227

ER -